Neogen Corporation (NEOG) fair value analysis
Nasdaq · Updated 2026-10-19
NEOG price how computed
Forward Fair Value verdict
Fairly valuedNEOG is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $11.81
- Sector
- Healthcare
- 12-month range
- $5.41–$13.98
- Market cap
- $2.58B
- From 52-week high
- -15.5%
- Shares outstanding
- 218M
- Rank in Healthcare by discount to fair value
- #103 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Neogen Corporation is a food and animal safety company that develops and manufactures testing and detection products for pathogens, allergens, and other contaminants in food and animal feed. The company operates globally across multiple continents, serving food producers, processors, and animal agriculture operations worldwide.
NEOG currently ranks #103 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 5 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $2.58B
- P/E (trailing)
- 35x
- Revenue (TTM)
- $884M
- Net margin
- -6.3%
- EPS (TTM)
- $0.34
- Gross margin
- 47.4%
- Debt / equity
- 0.37
- Revenue growth (3-yr avg)
- -1.0%
- Shares outstanding
- 218M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Expanding
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 43 · neutral
- 50-day average
- $12.16
- 200-day average
- $10.23
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Last 8 quarters vs consensus
- 5 beat, 1 missed
- Quarter by quarter
- 2026-08 ▲ beat (+75.0%)
2026-05 ▲ beat (+166.7%)
2026-02 ▲ beat (+80.0%)
2025-11 ▲ beat (+42.9%)
2025-08 ▬ met (0.0%)
2025-05 ▲ beat (+266.7%)
2025-02 ▼ miss (-16.7%)
2024-11 ▬ met (0.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 3 buy · 1 hold · 0 sell (4 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $14
- Target vs last price
- +18.5%
What our data shows for NEOG
- Our model validated 17 trailing price-to-earnings windows for NEOG, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $5.41–$13.98.
- The 14-day relative strength index sits at a neutral 43.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for NEOG
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent NEOG news
TickrTrends' derived news-sentiment signal for NEOG is currently leaning positive, computed from recent coverage.
- Neogen Corporation 2027 Q1 - Results - Earnings Call Presentation (NASDAQ:NEOG) 2026-10-10 (seekingalpha.com, 2026-10-10)
TickrTrends take: Neogen Corporation's Q1 2027 earnings presentation provides an opportunity to assess whether the company's operational performance supports its current fairly valued designation in the Healthcare sector. Investors monitoring valuation should focus on revenue trends, margin developments, and management guidance to determine if the fairly valued status remains appropriate or if fundamental shifts warrant a reassessment. The timing of this earnings disclosure allows valuation-conscious investors to evaluate whether current market pricing reflects the company's operational trajectory through early 2027. - Neogen Corporation Stock: Promising Recurring Demand With Food Safety (NASDAQ:NEOG) (seekingalpha.com, 2026-10-08)
TickrTrends take: Neogen Corporation operates in the Healthcare sector and currently trades at a valuation that TickrTrends assesses as fairly valued. The company's positioning around recurring demand in food safety represents a business model characteristic that valuation-focused investors typically monitor for predictability and margin sustainability. As Neogen's operations show signs of recurring revenue potential, investors should track whether the company can translate this demand stability into operational leverage that would support or challenge its current valuation standing. - Neogen Corporation (NEOG) Analyst/Investor Day - Slideshow (NASDAQ:NEOG) 2026-10-08 (seekingalpha.com, 2026-10-08)
TickrTrends take: Neogen Corporation held an analyst and investor day event, providing an opportunity for the market to reassess the company's strategic direction and financial outlook. Given that TickrTrends currently rates NEOG as fairly valued within the Healthcare sector, investors should monitor whether management's presentations at this event support or challenge the existing valuation consensus. Any material updates to growth projections, margin expectations, or capital allocation plans could shift the valuation assessment depending on how the market interprets the company's path forward.
What people are saying
Follow the NEOG conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — TickrTrends' derived indicators for NEOG showed improvement this week as the quality grade rose from F to D, while the sector discount rank improved from number 73 to number 59 within the Healthcare sector. The company maintains a Fairly valued valuation verdict as of the current assessment.
- 2026-10-10 — TickrTrends' derived indicators for NEOG showed mixed movement this week. The 50/200-day trend state shifted from uptrend to mixed, while the RSI zone moved from overbought to neutral territory. With a current valuation verdict of fairly valued, these technical indicator changes suggest a period of consolidation in the Healthcare sector stock.
- 2026-10-05 — TickrTrends' derived indicators for NEOG showed improvement this week as the company's sector discount rank advanced from 94 to 76 among healthcare sector peers. The valuation verdict shifted from Overvalued to Fairly valued, reflecting the stock's updated positioning within the Healthcare sector.
- 2026-09-28 — NEOG in the Healthcare sector moved into overbought territory this week as its RSI zone shifted from neutral to overbought. The stock's sector discount rank declined from number 74 to number 94, indicating reduced relative value positioning within its peer group. TickrTrends' valuation verdict changed from fairly valued to overvalued.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is NEOG stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), NEOG is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is NEOG's TickrTrends verdict?
NEOG's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does NEOG compare to other Healthcare stocks?
NEOG ranks #103 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is NEOG overbought or oversold?
NEOG's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does NEOG usually beat earnings estimates?
Over its last 8 reported quarters NEOG beat the consensus estimate 5 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about NEOG?
Of 4 analysts covering NEOG, 3 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $14 (+18.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
NEOG vs CLOV · NEOG vs ENSG · NEOG vs EXEL · NEOG vs FLGT · NEOG vs HCSG